Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02566681 |
Recruitment Status : Unknown
Verified March 2017 by Red de Terapia Celular.
Recruitment status was: Recruiting
First Posted : October 2, 2015
Last Update Posted : March 30, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteonecrosis of Jaw | Biological: MSC construct for Osteonecrosis | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM) |
Study Start Date : | September 2015 |
Estimated Primary Completion Date : | December 2018 |
Estimated Study Completion Date : | December 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: MSC construct for Osteonecrosis
Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
|
Biological: MSC construct for Osteonecrosis
30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA). Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days. The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures. |
- Rate of serious adverse events related to the procedure. [ Time Frame: 24 months from baseline ]Apparition of Bone ischemic events. Neoformations.
- Rate of non-serious adverse events related to the procedure. [ Time Frame: 24 months from baseline ]Local infection of the surgical wound. Pseudarthrosis implant. Allergic reactions.
- Time to Repair the injury [ Time Frame: 24 months from baseline ]
- Local pain assessed by visual analog scale [ Time Frame: 24 months from baseline ]
- Bone formation, measured by Computed tomography (mm) [ Time Frame: 24 months from baseline ]
- Quality of life, measured by EuroQol-5D. [ Time Frame: 24 months from baseline ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of mandibular osteonecrosis of any etiology defined by clinical and radiological examination.
- Bone defect anteroposterior dimension less than or equal to 4 cm in the mandible or the maxilla 2.5, and / or bone bed sufficient to ensure the integrity of the construct during surgery.
- No response to conservative treatment.
- Provide sufficient assurance of adherence to protocol.
- Provide written consent
- Meet all the inclusion criteria
Exclusion Criteria:
- Concomitant psychiatric illness.
- Uncontrolled concomitant systemic disease.
- Active infectious disease in the focus of mandibular osteonecrosis.
- Neoplastic disease in complete remission less than 2 years.
- Pregnant patients.
- Patients with active feeding.
- Patients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.
- Patients with cardiac disease, renal, hepatic, systemic, immune that may influence patient survival during the test.
- Inclusion in other clinical trials in active treatment.
- Inability to understand the informed consent.
- You need not meet any exclusion criteria

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02566681
Contact: Natalia García Iniesta | +34968381221 | nagarini@yahoo.es |
Spain | |
Hospital Clínico Virgen de la Arrixaca | Recruiting |
El Palmar, Murcia, Spain, 30120 | |
Contact: Natalia García Iniesta +34968381221 nagarini@yahoo.es | |
Principal Investigator: Victor Villanueva San Vicente, MD | |
Principal Investigator: Francisco J Rodríguez Lozano, PhD | |
Sub-Investigator: María A Rodríguez González, MD | |
Sub-Investigator: Daniel Segarra Fenoll, MD | |
Sub-Investigator: María M Gonzálvez García, MD | |
Sub-Investigator: José M Moraleda Jiménez, MD | |
Sub-Investigator: Miguel Blanquer Blanquer, MD | |
Sub-Investigator: Ana M García Hernández, MD | |
Sub-Investigator: Joaquín A Gómez Espuch, MD | |
Sub-Investigator: María Dolores López Lucas, Graduate | |
Sub-Investigator: Darío Sánchez Salinas, Graduate | |
Sub-Investigator: Francisca Iniesta Martínez, Graduate | |
Sub-Investigator: Carmen Algueró Martín, Graduate | |
Sub-Investigator: Francisca Velázquez Marín, MD | |
Sub-Investigator: Ricardo Oñate Sánchez, MD | |
Sub-Investigator: Luis Meseguer Olmo, MD |
Principal Investigator: | Victor Villanueva San Vicente, MD | Hospital Universitario Virgen de la Arrixaca | |
Principal Investigator: | Francisco J Rodríguez Lozano, PhD | Universidad de Murcia |
Responsible Party: | Red de Terapia Celular |
ClinicalTrials.gov Identifier: | NCT02566681 |
Other Study ID Numbers: |
MSC/ONM 2012-005813-38 ( EudraCT Number ) |
First Posted: | October 2, 2015 Key Record Dates |
Last Update Posted: | March 30, 2017 |
Last Verified: | March 2017 |
Osteonecrosis Bone Diseases Musculoskeletal Diseases Necrosis Pathologic Processes |